Gain Therapeutics, Inc. (GANX)
NasdaqGM
Fundamentals
Valuation and ratings
Gain Therapeutics, Inc. trades at USD1.75. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Super investor ownership
3 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Marshall Wace, MARSHALL WACE, LLP$3.43M · 0.0% of book
- David Einhorn, GREENLIGHT CAPITAL INC$1.92M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$48.3K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own GANX?
3 of the institutions we track reported a position in GANX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for GANX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.